| 4.92 0.16 (3.36%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.58 |
1-year : | 7.69 |
| Resists | First : | 5.63 |
Second : | 6.58 |
| Pivot price | 4.81 |
|||
| Supports | First : | 4.66 |
Second : | 4.07 |
| MAs | MA(5) : | 4.79 |
MA(20) : | 4.71 |
| MA(100) : | 4.92  |
MA(250) : | 4.68 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 37.8 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 9.75 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NUVB ] has closed below upper band by 31.0%. Bollinger Bands are 57.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.22 - 5.24 | 5.24 - 5.26 |
| Low: | 4.81 - 4.83 | 4.83 - 4.85 |
| Close: | 4.88 - 4.92 | 4.92 - 4.95 |
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Mon, 08 Jun 2026
Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) (NYSE:NUVB) - Seeking Alpha
Tue, 26 May 2026
Nuvation Bio (NUVB) director gets 123,397 stock options at $4.79 - Stock Titan
Fri, 08 May 2026
Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
Mon, 04 May 2026
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 347 (M) |
| Held by Insiders | 2.3762e+008 (%) |
| Held by Institutions | 18.5 (%) |
| Shares Short | 50,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4821e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -102.1 % |
| Operating Margin | 4.6 % |
| Return on Assets (ttm) | -17.1 % |
| Return on Equity (ttm) | -39.6 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 393.88 |
| Sales Per Share | 9.41118e+007 |
| EBITDA (p.s.) | 8.54276e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 8.12 |
| Dividend | 0 |
| Forward Dividend | 5.149e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|